Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Akero Therapeutics ( (AKRO) ) has provided an update.
On December 9, 2025, Akero Therapeutics announced the consummation of a merger agreement that resulted in the company becoming a wholly owned subsidiary of another entity. As part of this merger, Akero Therapeutics notified Nasdaq of its intent to delist its common stock, which will be suspended from trading on December 10, 2025. The merger led to a change in control, with all previous directors and executive officers resigning and being replaced by the directors and officers of the acquiring company. The company’s certificate of incorporation and bylaws were also amended to reflect the merger agreement.
The most recent analyst rating on (AKRO) stock is a Hold with a $54.00 price target. To see the full list of analyst forecasts on Akero Therapeutics stock, see the AKRO Stock Forecast page.
Spark’s Take on AKRO Stock
According to Spark, TipRanks’ AI Analyst, AKRO is a Neutral.
Akero’s stock score reflects strong technical momentum and positive corporate developments, which are key drivers. However, financial challenges with no current revenue and operational losses weigh down the overall score. The promising clinical trial results provide a potential catalyst for future growth.
To see Spark’s full report on AKRO stock, click here.
More about Akero Therapeutics
Average Trading Volume: 2,581,741
Technical Sentiment Signal: Buy
Current Market Cap: $4.49B
Find detailed analytics on AKRO stock on TipRanks’ Stock Analysis page.